Corvus Pharmaceuticals, Inc. (CRVS) Reports In-Line Q3 EPS

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) reported Q3 EPS of ($0.12), in-line with the analyst estimate of ($0.12).

For earnings history and earnings-related data on Corvus Pharmaceuticals, Inc. (CRVS) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates
• Jaguar Health (JAGX) Tops Q2 EPS by 3647c